Home » Business News » 2012 » April » April 4, 2012

Ablynx's Partner Shows That a Nanobody Can Elicit Superior Anti-Tumour Efficacy Compared to Conventional Monoclonal Antibody Approaches

April 4, 2012 - Ghent, Belgium

Ablynx (Euronext Brussels: ABLX) today notedthata paper on a novel tetrameric Nanobody(®) agonist (TAS266)targeting DeathReceptor 5 (DR5), a key receptor target on cancer cells across anumber oftumour types, was presented at the American Association for CancerResearchAnnual Meeting in Chicago, USA, on 3 April 2012 by Novartis. Theability ofTAS266 to efficiently 'cross-link' DR5 receptor targets, apparentlynotachievable with conventional monoclonal antibodies, results in thecontrolleddeath of cancer cells.

The paper was presented by Dr Heather Huet from Novartis and theauthorsincluded three scientists from Ablynx.

The abstract summarizes the results of the pre-clinical in vitro and invivostudies of a tetravalent anti-DR5 Nanobody in an oncology setting.TAS266 wasshown to elicit sustained tumour regressions in multiple tumourxenograftmodels, including a patient-derived primary pancreatic tumour modelthat isinsensitive to a conventional anti-DR5 agonist antibody. Also, compared tosomeof the other therapeutic agonists against DR5 that have been developed andthathave been clinically evaluated, TAS266 proved to be up to 1000-fold morepotentin tumour cell death assays.

In view of this, the authors of the abstract conclude that "TAS266has thepotential for superior clinical activity in settings insensitive totheconventional therapeutic approaches to DR5."

The abstract further states that "first-in-man trials for TAS266 areexpected tobegin in 2012."

Link to the presentation abstract: "TAS266, a novel tetrameric Nanobodyagonisttargeting death receptor 5 (DR5), elicits superior anti-tumour efficacythanconventional DR5-targeted approaches."

Commenting on today's announcement, Dr Edwin Moses, Chairman and CEO ofAblynx,said:

"Being present on cancer cells across a broad range of tumour types,DR5 hasbeen the target of numerous conventional antibody approaches, but nonehaveapparently been successful so far, possibly because of the need forsecondary'cross-linking' to achieve the required activity. The ability toproducetetravalent Nanobodies appears to allow more efficient 'cross-linking'(in thetumour micro-environment) and so potentially opens up a new pathwayfor thetreatment of certain cancers."

About Ablynx

Ablynx is a biopharmaceutical company engaged in the discovery anddevelopmentof Nanobodies(®), a novel class of therapeutic proteins based onsingle-domainantibody fragments, for a range of serious and life-threatening humandiseases,including inflammation, haematology, oncology and pulmonary disease.Today, theCompany has over 25 programmes in the pipeline and seven Nanobodies atclinicaldevelopment stage. Ablynx has ongoing research collaborations andsignificantpartnerships with major pharmaceutical companies, includingBoehringerIngelheim, Merck Serono and Novartis. The Company is headquartered inGhent,Belgium. More information can be found on

Complete version of the press release:

This announcement is distributed by Thomson Reuters on behalf ofThomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Ablynx via Thomson Reuters ONE


For more information, please contact

Dr Edwin Moses
Chairman and CEO
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
+32 (0)473 39 50 68
e: Email Contact

Marieke Vermeersch
Investor Relations Manager
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e: Email Contact

M: Communications:
Mary-Jane Elliott
Amber Bielecka
Claire Dickinson
t: +44 207 920 2330
e: Email Contact


Comment on this story